Final Agenda:
MARCH 2, 2010
Registration Opens: 9am - 5pm
Morning Sessions
Session Chair: John Shiver, Connie Schmaljohn
10:00 — 10:30AM
Welcome Address from the Program Chairman: Enhancing DNA Vaccine Immunity in Vivo
David B. Weiner, PhD — University of Pennsylvania
10:30 — 11:00AM
The Future of Vaccines from an Industry Perspective
John Shiver, PhD — Merck
11:00 — 11:30AM
Human Immune Responses to Vaccination
Mark Slifka, PhD — OSHU
11:30 — 12:00AM
Preclinical and Clinical Studies of DNA Vaccines for Biodefense
Connie Schmaljohn, PhD — USAMRIID
12:00 — 1:10PM Lunch Opens
Afternoon Session 1
Session Chairs: Iacob Matheson, Shan Lu
1:10 — 1:30PM
Live Attenuated Influenza Vaccine for Seasonal and Pandemic Applications
Hong Jin — Medimmune
1:30 — 1:50PM
The Strengths and Weaknesses of Inducing Mismatched Immunity to Expand Cross-Protection Against Influenza Viruses
Gary Kobinger, PhD — PHAC
1:50 — 2:10PM
Approaches to Influenza
Jukka Hartikka, PhD — Vical
2:10 — 2:30PM
SynCon™ DNA Vaccines for Infectious Diseases
NiranJan Sardesai, PhD — Inovio Biomedical Corporation
2:30 — 3:00PM
Approaches to HCV DNA Vaccines
Matti Sällberg, PhD — Tripep Pharma
3:00 — 3:30PM Break
Afternoon Session 2
Session Chairs: T.C. Wu, Gary Kobinger
3:30 — 3:50PM
Immunogenicity of VRC DNA Vaccines for HIV, WNV and Influenza
Julie Ledgerwood — VRC
3:50 — 4:10PM
T Cell Responses in Prostate Cancer Patients Immunized with Xenogeneic and Syngeneic PSMA DNA Vaccines
Polly Gregor, PhD — MSKCC
4:10 — 4:30PM
Therapeutic HPV DNA Vaccine Development
T.C. Wu, MD, PhD — The Johns Hopkins Medical Institutions
4:30 — 4:45PM
The PEDVAC Trial: Preliminary Safety Data from the First Therapeutic DNA Vaccination in HIV-Infected Children
Britta Wahren, MD, PhD — Karolinska Institute
4:45 — 5:00PM
Immunization with Drug-Resistant HIV-1 Enzyme Genes
Maria Isaguliants — Karolinska Institute
5:00 — 7:30PM Cocktail Social Hour in Exhibits Poster Area
MARCH 3, 2010
8:00 — 9:00AM Breakfast
Morning Session 1
Session Chairs: Mark Bagarazzi, Jeffrey Ulmer
9:00 — 9:30AM
RV 144 ALVAC-HIV/AIDSVAX Study: Implications for HIV Vaccine Development
Col. Nelson Michael, MD, PhD — Walter Reed Army Institute of Research, US Military HIV Research Program (MHRP)
9:30 — 10:00AM
Technologies for Improved Vaccines
Jeffrey Ulmer, PhD — Novartis Vaccines & Diagnostics
10:00 — 10:30AM
Mucosal Immunology of SIV Infection
Ron Veazey, DVM, PhD — Tulane University
10:30 — 11:00AM Break
Morning Session 2
Session Chairs: Jim Mullins, Harriet Robinson
11:00 — 11:20AM
What is a Protective T Cell Response
Michael Betts, PhD — University of Pennsylvania School of Medicine
11:20 — 11:40AM
Heterologous Prime-Boost HIV Vaccines
Shan Lu, MD, PhD — University of Massachusetts Medical School
11:40 — 12:00PM
Studies in Preclinical Macaque Models of DNA/MVA Vaccines
Harriet L. Robinson, PhD — Geovax Inc.
12:00 — 1:10PM Lunch Break
Afternoon Session 1
Session Chairs: George Pavlakis, Susan Zolla-Pazner
1:10 — 1:30PM
Clinical Experiences of HIV Genetic Vaccines
Britta Wahren, MD, PhD — Karolinska Institute
1:30 — 1:50PM
Optimization of DNA and Combination Vaccines in Macaques
George Pavlakis, MD, PhD — NCI
1:50 — 2:10PM
Induction of Cross-clade Neutralizing Antibodies with a Prime/Boost Vaccine Strategy Focused on a Neutralizing Epitope
Susan Zolla-Pazner, PhD — NYU Medical School
2:10 — 2:30PM
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers
Sandhya Vasan, MD — Aaron Diamond AIDS Research Center
2:30 — 2:50PM
Genomic Signatures of DNA Vaccines
Jean Boyer, PhD — University of Pennsylvania
2:50 — 3:10PM Break
Afternoon Session 2
Session Chairs: Michael Betts, Matti Sallberg
3:10 — 3:30PM
Conserved Elements Vaccine for HIV-1 Gagp24 is Immunogenic in Mice and Macaques
James Mullins, PhD — University of Washington
3:30 — 3:45PM
Co-Delivery of Mucosal Chemokine Plasmids in a Systemically Administered DNA Vaccine Elicits Systemic and Mucosal Immune Reponses in Rhesus Macaques
Michele Kutzler — Drexel University
3:45 — 4:00PM
In Vivo Intracellular Injection Needle (IvIn) Technology: A New Needle for Improved Cellular Uptake of DNA in a Live Animal
Lars Frelin — Karolinska Insitute
4:00 — 4:15PM
An Adjuvanted Therapeutic DNA Vaccine Enhances Mucosal T-Cell Responses, Reduces Virus in the Gut, and Prevents Viral Rebound in Rhesus Macaques Chronically Infected with SIV
Deborah Fuller — Albany Medical College
Industry Discussion Panel - Chair: David Weiner
4:15 — 5:00PM
Panel Discussion:
Stanley Plotkin, Joseph Kim, Andrew Murdin, Tim Leard, Jeffrey Ulmer
Dinner Speaker:
Special Invited Speaker: Correlates of Protection from Infection
Stanley Plotkin, MD — Vaxconsult LLC introduced by Andrew Murdin - Sanofi Aventis
Presentation of Maurice Hilleman Award - David Kaslow
Presentation of Richard Ginsberg Award - David Weiner
5:30 - 7:00PM Cocktail Social Hour in Exhibits Poster Area
7:00PM Gala Dinner in Banquet Hall
MARCH 4, 2010
8:00 — 9:00AM Breakfast
Morning Session 1
Session Chairs: Henry Hebel, James Williams
9:00 — 9:15AM
Developing a Successful Contact Manufacturing Organization Partnership: A Case Study
Henry Hebel — VGXi
9:15 — 9:30AM
DNA Vaccine Purification: Increasing Productivity and Purity of Plasmid DNA by Monolith Chromatography
Matjaz Peterka — BIA Separations
9:30 — 9:45AM
Improved Antibiotic-Free Plasmid Vector Design by Incorporation of Transient Expression Enhancers
James Williams — Nature Technology
9:45 — 10:00AM
Accelerating the Development and Commercialization of DNA Vaccines
Magda Marquet, PhD — Althea Technologies
10:00 — 10:20AM
Comparative Performance Evaluation of Electroporation Mediated DNA Immunization Versus Conventional Vaccine Approaches
Drew Hannaman, PhD — Ichor Medical Systems
10:20 — 10:50AM Break
Morning Session 2
Session Chairs: Bin Wang, Ruxandra Draghia-Akli
10:50 — 11:10AM
Antigen Specific Immunity after CTLA-4 Blockade: Investigating the Role of Prior Vaccination
Jianda Yuan, MD, PhD — MSKCC
11:10 — 11:30AM
Canine Melanoma Vaccine, DNA, A Review of Efficacy and Licensure
Tim Leard, DVM, PhD — Merial
11:30 — 11:50AM
Tolerogenic Vaccination to Induce Antigen Specific T Regulatory Cells to Suppress Inflammatory Responses
Bin Wang, PhD — China Agricultural University
11:50 — 12:10PM
DNA Vaccine Based on Cancer-Testis Antigen, BORIS and IL21 Molecular Adjuvant in Extremely Effective For Treatment of Metastatic Disease
Michael Agadjanyan, PhD — The Institute for Molecular Medicine
12:10 — 1:20PM Lunch
Afternoon Session
Session Chair: David Kaslow, Ashley Birkett
1:20 — 1:40PM
Recent Advances in Malaria Vaccine Development
Ashley Birkett, PhD — PATH MVI
1:40 — 2:00PM
Transformative Technologies in the Vaccine Area - How Will We Know?
David Kaslow, MD — Merck
2:00 — 2:15PM
Structure and Biological Activity of Synthetic DNA Vaccines Formulated to Nanomedicines
Julianna Lisziewicz, PhD — Genetic Immunity
2:20 — 2:35PM
Prototype Development and Pre-Clinical Immunogenicity Analysis of a Novel Minimally Invasive Electroporation Device
Kate Broderick, PhD — Inovio Biomedical Corporation
2:30 — 3:00PM Break
Vaccine Stakeholder Panel - Chair: Ray Spier
3:00 — 3:45PM
DNA Vaccines: A View from Both Sides of the Fence and Both Sides of the Pond
Panel Discussion - David Kaslow, Ruxandra Draghia-Akli, Ashley Birkett, Jeffrey Ulmer
3:45 — 4:00PM Closing Session Summary – Niranjan Sardesai, Britta Wahren & David Weiner